Back to Newsroom

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported financial results and business highlights for the third quarter ended September 30, 2016.

Click here to read the full release